Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Inclusion Criteria:

• Participant has histologically or cytologically proven advanced or metastatic NSCLCand only squamous or non-squamous cell carcinoma.

• Participant has received no more than 2 prior lines of therapy for advanced ormetastatic disease, which must only include a platinum based (e.g., cisplatin,carboplatin) doublet chemotherapy regimen and an anti-PD-1 or an anti-PD-(L)1antibody.

• Participant has measurable disease.

• Participant has documented radiographic disease progression on prior platinum basedchemotherapy and on or after prior anti-PD-(L)1 therapy.

• Participant agrees to submit an archival formalin-fixed paraffin-embedded (FFPE)tumor tissue specimen that was collected on or after diagnosis of metastaticdisease. If archival tissue is not available, the participant must undergo biopsyprior to study entry.

• Participant has an ECOG performance status score of 0 or 1.

• Participant has a life expectancy of at least 3 months.

• Participant has adequate Baseline organ function.

• Participant has recovered from any prior treatment related toxicities.

• Participant agrees to use contraception.

Exclusion Criteria:

• Participant has been previously treated with an anti-PD-[L]1 or anti-programmeddeath-ligand 2 (anti-PD-[L]2) agent that resulted in permanent discontinuation dueto an AE.

• Participant has been previously treated with an anti-T cell immunoglobulin and mucindomain containing 3 (anti-TIM-3) or anti-cytotoxic T lymphocyte associated protein 4 (CTLA 4) agent or docetaxel.

• Participant has a documented sensitizing epidermal growth factor receptor (EGFR),anaplastic lymphoma kinase (ALK), or c-ros oncogene 1 (ROS-1) mutation. Participantswhose tumors have not been tested for these driver mutations and therefore who haveunknown driver mutation status are not eligible. Participants with squamoushistology do not need to be tested for these driver mutations.

• Participant had radiological or clinical disease progression (i.e., worseningperformance status, clinical symptoms, and laboratory data) <=8 weeks afterinitiation of prior anti-programmed cell death protein 1 (anti-PD-1) or anti-PD-L1antibody. The clinical disease progression should have been confirmed by asubsequent radiological scan.

• Participant has received radiation to the lung that is >30 gray (Gy) within 6 monthsprior to the first dose of study treatment.

• Participant has completed palliative radiotherapy within 7 days prior to the firstdose of study treatment.

• Participant is ineligible if any of the following hepatic characteristics arepresent: a. Alanine aminotransferase (ALT) >2.5 times upper limit normal (ULN) b.ALT and/or aspartate aminotransferase (AST) >1.5 times ULN concomitant with alkalinephosphatase (ALP) >2.5 times ULN; c. Bilirubin >1 times ULN; d. Current active liveror biliary disease (with the exception of Gilbert's syndrome or asymptomaticgallstones, liver metastases, or otherwise stable chronic liver disease per theInvestigator's assessment).

• Participant has known new or progressive brain metastases and/or leptomeningealmetastases. Participants who have received prior therapy for their brain metastasesand have radiographically stable central nervous system disease may participate,provided they are neurologically stable for at least 4 weeks before study entry andare off corticosteroids within 3 days prior to the first dose of study treatment.

• Participant has tested positive for the following at Screening or within 3 monthsbefore the first dose of study treatment: a. Presence of hepatitis B surfaceantigen. b. Presence of hepatitis C antibody in the absence of a ribonucleic acid (RNA) test for hepatitis C virus. If a confirmatory RNA test is available, apositive test result will exclude a participant, while a negative test result (indicating absence of active infection) will allow the participant to enter intothe study.

• Participant has known human immunodeficiency virus (HIV) (positive for HIV 1 or HIV 2 antibodies).

• Participant has active autoimmune disease that required systemic treatment in thepast 2 years, is immunocompromised in the opinion of the Investigator, or isreceiving systemic immunosuppressive treatment.

• Participant has symptomatic ascites or pleural effusion. A participant who isclinically stable following treatment of these conditions (including therapeuticthoracentesis or paracentesis) is eligible.

• Participant has current interstitial lung disease, current pneumonitis, or a historyof pneumonitis that required the use of glucocorticoids to assist with management.

• Participant has pre-existing peripheral neuropathy that is Grade >=2 by NationalCancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 criteria.

• Participant has received a live vaccine within 30 days of the first dose of studytreatment. Seasonal flu vaccines that do not contain live virus and CoronavirusDisease 2019 (COVID-19) vaccines.

• Participant is unable to interrupt aspirin or other non-steroidal anti-inflammatorydrugs (NSAIDs) for undergoing a biopsy procedure (in cases when a participant doesnot have an archival biopsy), other than an aspirin dose <=1.3 grams (g) per day,for a 5-day period (8-day) period for long-acting agents, such as piroxicam).